BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29207909)

  • 1. The Evolving Role of Long-Term Pharmacotherapy for Opioid-Induced Constipation in Patients Being Treated for Noncancer Pain.
    Bowers BL; Crannage AJ
    J Pharm Pract; 2019 Oct; 32(5):558-567. PubMed ID: 29207909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid-induced constipation in chronic noncancer pain.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):11-7. PubMed ID: 26702846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence Based Review of Pharmacotherapy for Opioid-Induced Constipation in Noncancer Pain.
    Murphy JA; Sheridan EA
    Ann Pharmacother; 2018 Apr; 52(4):370-379. PubMed ID: 29092627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lubiprostone for Opioid-Induced Constipation Does Not Interfere with Opioid Analgesia in Patients with Chronic Noncancer Pain.
    Spierings EL; Brewer RP; Rauck RL; Losch-Beridon T; Mareya SM
    Pain Pract; 2017 Mar; 17(3):312-319. PubMed ID: 26990171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Overview and Considerations for the Management of Opioid-induced Constipation in Patients With Chronic Noncancer Pain.
    Viscusi ER
    Clin J Pain; 2019 Feb; 35(2):174-188. PubMed ID: 30289777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
    Holder RM; Rhee D
    Pharmacotherapy; 2016 Mar; 36(3):287-99. PubMed ID: 26945548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
    Wild J; Webster L; Yamada T; Hale M
    Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain.
    Cryer B; Katz S; Vallejo R; Popescu A; Ueno R
    Pain Med; 2014 Nov; 15(11):1825-34. PubMed ID: 24716835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation.
    White WB; Kowey P; Diva U; Sostek M; Tummala R
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):309-317. PubMed ID: 29504415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class.
    Webster LR; Brewer RP; Lichtlen P; Losch-Beridon T; Mareya S; Wang M
    Pain Med; 2018 Jun; 19(6):1195-1205. PubMed ID: 29897589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
    Rauck R; Slatkin NE; Stambler N; Harper JR; Israel RJ
    Pain Pract; 2017 Jul; 17(6):820-828. PubMed ID: 27860208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis.
    Nee J; Zakari M; Sugarman MA; Whelan J; Hirsch W; Sultan S; Ballou S; Iturrino J; Lembo A
    Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1569-1584.e2. PubMed ID: 29374616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.
    Jamal MM; Adams AB; Jansen JP; Webster LR
    Am J Gastroenterol; 2015 May; 110(5):725-32. PubMed ID: 25916220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid-Induced Constipation.
    Webster L; Diva U; Tummala R; Sostek M
    Pain Pract; 2018 Apr; 18(4):505-514. PubMed ID: 28898536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and systematic review.
    Mehta N; O'Connell K; Giambrone GP; Baqai A; Diwan S
    Postgrad Med; 2016; 128(3):282-9. PubMed ID: 26839023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of opioid-induced constipation.
    Prichard D; Norton C; Bharucha AE
    Br J Nurs; 2016 May 26-Jun 8; 25(10):S4-5, S8-11. PubMed ID: 27231750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials.
    Wild J; Yamada T; Arjona Ferreira JC; Hale M
    Pain; 2019 Oct; 160(10):2358-2364. PubMed ID: 31145214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of oral naloxegol vs subcutaneous methylnaltrexone in treatment of opioid-induced constipation in the hospital setting.
    Nero R; Allen B; Hailu K; Noor R; Theiss K
    Am J Health Syst Pharm; 2023 May; 80(Suppl 2):S70-S76. PubMed ID: 36440903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the recognition and diagnosis of opioid-induced constipation in clinical practice.
    Gupta A
    J Fam Pract; 2015 Oct; 64(10 Suppl 1):. PubMed ID: 26561554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes.
    Spierings ELH; Drossman DA; Cryer B; Mazen Jamal M; Losch-Beridon T; Mareya SM; Wang M
    Pain Med; 2018 Jun; 19(6):1184-1194. PubMed ID: 29016868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.